MONMOUTH JUNCTION, N.J., Dec. 20, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the launch and initial sales of its new CytoSorb® Cardio-Pulmonary Bypass (CPB) Procedure Pack for cardiac surgery. This new product provides all of the necessary components, including the CytoSorb cartridge, to rapidly and seamlessly integrate CytoSorb into the majority of heart-lung machines used in open heart surgery today. CytoSorb has been used intra-operatively in thousands of heart operations in Europe to either help stabilize unstable patients during surgery or to prophylactically treat patients at risk of severe inflammation caused by the surgery.
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "The CytoSorb CPB Procedure Pack was developed by our product management and engineering teams with key input from cardiac surgeons and perfusionists. It is the first of a series of value added procedure kits that we plan to introduce into the market in 2017 to improve the end-user experience."
Mr. Capponi continued, "We are also delighted to count our partner, Terumo Cardiovascular Group, among the first customers to have ordered the CytoSorb CPB Procedure Pack. We have worked closely with Terumo, a global leader in cardiac and vascular surgery, to finalize all documentation, marketing material, and sales force training, and are pleased that they have now officially launched sales of CytoSorb in their exclusive market territories of France, Denmark, Sweden, Finland, Norway, and Iceland."
The CytoSorb CPB Procedure Pack is now available for volume purchase by direct customers and distributors worldwide.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 17,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $20 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytosorbents-announces-first-sales-of-new-cytosorb-cpb-procedure-pack-for-cardiac-surgery-300381836.html
SOURCE CytoSorbents Corporation